End-of-day quote
Dhaka S.E.
06:00:00 2024-07-10 pm EDT
|
5-day change
|
1st Jan Change
|
20.6
BDT
|
-2.83%
|
|
-1.90%
|
-11.97%
|
Fiscal Period: Giugno |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,322
|
2,325
|
2,709
|
2,741
|
2,533
|
Enterprise Value (EV)
1 |
2,020
|
2,067
|
2,645
|
2,680
|
2,483
|
P/E ratio
|
10.8
x
|
28
x
|
32
x
|
32.5
x
|
36.6
x
|
Yield
|
0.81%
|
4.46%
|
3.83%
|
1.89%
|
1.23%
|
Capitalization / Revenue
|
2.53
x
|
3.17
x
|
4.51
x
|
4.9
x
|
5.45
x
|
EV / Revenue
|
2.2
x
|
2.82
x
|
4.4
x
|
4.79
x
|
5.34
x
|
EV / EBITDA
|
9.02
x
|
11.8
x
|
17.2
x
|
15.6
x
|
16.1
x
|
EV / FCF
|
-115
x
|
-39.5
x
|
-18.6
x
|
74
x
|
-213
x
|
FCF Yield
|
-0.87%
|
-2.53%
|
-5.39%
|
1.35%
|
-0.47%
|
Price to Book
|
1.06
x
|
1.04
x
|
1.19
x
|
1.2
x
|
1.09
x
|
Nbr of stocks (in thousands)
|
103,807
|
103,807
|
103,807
|
103,807
|
103,807
|
Reference price
2 |
22.36
|
22.40
|
26.10
|
26.40
|
24.40
|
Announcement Date
|
10/26/20
|
11/1/20
|
8/29/21
|
12/19/22
|
1/5/24
|
Fiscal Period: Giugno |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
917.8
|
919
|
733.7
|
601.1
|
559.5
|
464.7
|
EBITDA
1 |
250.1
|
223.9
|
175.6
|
154
|
172.2
|
153.9
|
EBIT
1 |
162.9
|
141.5
|
96.96
|
79.39
|
97.48
|
67.18
|
Operating Margin
|
17.75%
|
15.39%
|
13.22%
|
13.21%
|
17.42%
|
14.46%
|
Earnings before Tax (EBT)
1 |
162.1
|
141.8
|
110.9
|
89.63
|
109
|
89.24
|
Net income
1 |
105.4
|
162.5
|
83.18
|
84.65
|
84.45
|
69.22
|
Net margin
|
11.48%
|
17.68%
|
11.34%
|
14.08%
|
15.09%
|
14.9%
|
EPS
2 |
1.488
|
2.077
|
0.8013
|
0.8154
|
0.8135
|
0.6668
|
Free Cash Flow
1 |
-13.7
|
-17.62
|
-52.35
|
-142.5
|
36.24
|
-11.67
|
FCF margin
|
-1.49%
|
-1.92%
|
-7.14%
|
-23.71%
|
6.48%
|
-2.51%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
21.05%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
42.91%
|
-
|
Dividend per Share
|
-
|
0.1818
|
1.000
|
1.000
|
0.5000
|
0.3000
|
Announcement Date
|
2/11/19
|
10/26/20
|
11/1/20
|
8/29/21
|
12/19/22
|
1/5/24
|
Fiscal Period: Giugno |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
15.7
|
302
|
258
|
64.6
|
60.5
|
49.7
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-13.7
|
-17.6
|
-52.4
|
-143
|
36.2
|
-11.7
|
ROE (net income / shareholders' equity)
|
6.24%
|
8.28%
|
3.76%
|
3.75%
|
3.71%
|
3.01%
|
ROA (Net income/ Total Assets)
|
4.92%
|
3.75%
|
2.32%
|
1.85%
|
2.25%
|
1.53%
|
Assets
1 |
2,140
|
4,332
|
3,587
|
4,567
|
3,753
|
4,523
|
Book Value Per Share
2 |
24.60
|
21.00
|
21.60
|
21.80
|
22.00
|
22.30
|
Cash Flow per Share
2 |
0.2200
|
2.910
|
0.9800
|
0.5100
|
0.2600
|
0.3000
|
Capex
1 |
81.2
|
75.5
|
170
|
376
|
106
|
182
|
Capex / Sales
|
8.85%
|
8.21%
|
23.18%
|
62.63%
|
18.97%
|
39.15%
|
Announcement Date
|
2/11/19
|
10/26/20
|
11/1/20
|
8/29/21
|
12/19/22
|
1/5/24
|
|
1st Jan change
|
Capi.
|
---|
| -11.97% | 18.18M | | +62.66% | 854B | | +40.42% | 636B | | -4.37% | 361B | | +17.16% | 324B | | +9.87% | 301B | | +15.66% | 247B | | +17.90% | 228B | | +14.86% | 177B | | +0.45% | 164B |
Other Pharmaceuticals
|